30 closest matches · ranked by relevance
Aggressive Systemic Mastocytosis · Mast Cell Leukemia · Systemic Mastocytosis
Primary: Overall Response Rate (ORR) Per Consensus International Response Criteria (Rate of Complete or Partial Remissions or Clinical Improvement) — 0 participants
Systemic Mastocytosis, Aggressive (ASM) · Leukemia, Mast Cell · Hematological Non-mast Cell Lineage Disease (AHNMD)
Primary: Subjects With Clinical Response [Partial Response (PR) + Complete Response (CR)] — 25 participants
Leukemia
Primary: Percentage of Participants With Overall Response Rate (ORR) — 59.6 Percentage of participants — p=<0.001
Asthma · Mastocytosis · Mast Cell Activation Syndrome
Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Diseases
Primary: Clinical Response (Complete and Partial) — 0; 4; 4; 5 Participants
Chronic Myelomonocytic Leukemia · Chronic Myeloid Leukemia · Polycythemia Vera
Primary: Number of Participants With a Complete Response (CR) — 0; 0; 2; 0 participants
Hairy Cell Leukemia
Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants
Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Response (Complete and Partial Response) in Patients With Myeloid Disorders — 0; 1; 2; 5 Participants
Advanced Systemic Mastocytosis · Aggressive Systemic Mastocytosis · Systemic Mastocytosis With an Associated Hematologic Neoplasm
Primary: Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on…
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Myelodysplastic Syndrome (MDS) · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Number of Participants Who Experienced Inducing or Boosting of a Cellular Immune Response — 5; 2 participants
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Leukemia · Lymphocytic · Chronic
Primary: Response Rate — 0; 1; 3; 11 Participants
Leukemia
Primary: Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 — 0; 0; 1; 1 participants
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Leukemia
Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants
Hematologic Malignancies · Bone Marrow Transplant Rejection
Primary: The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30 — 44.9 percentage of participants
ALL · B Cell Lymphoma · Leukemia
Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Adult T-Cell Leukemia (ATL)
Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants
HTLV-I Infection · T Cell Leukemia
Primary: Duration of Response — 114 Weeks
Myeloid Leukemia, Chronic, Accelerated Phase · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…
Myeloid Malignancies · Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants Who Experienced Graft Failure — 0 Participants
Leukemia
Primary: Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. — 3; 2; 1; 1…
Leukemia · AML · MDS
Primary: Participants With a Complete Response — 34 Participants
Leukemia, Myelocytic, Acute
Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients
Leukemia · Lymphoma
Primary: Engraftment — 15; 15 days
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants